Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Dec;48(6):992-3.
doi: 10.1002/mus.24063. Epub 2013 Oct 7.

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment

John S Yi  1 , Emily C Decroos, Donald B Sanders, Kent J Weinhold, Jeffrey T Guptill
Affiliations
Case Reports

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment

John S Yi et al. Muscle Nerve. 2013 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Prolonged B cell depletion 34 months after rituximab treatment. Peripheral blood mononuclear cells from a healthy control, a patient with MuSK-MG, and our patient with MuSK-MG treated with rituximab were surface stained with CD19 PcP Cy5.5 conjugate. In order to isolate lymphocytes, a dump channel stained for CD3, CD14, and CD16 Pacific-Blue along with LIVE/DEAD dye conjugated to the same fluorophore was used to gate out macrophages, neutrophils, NK cells, dendritic cells, and dead cells. B cell populations are indicated by the circles. The logarithmic scales on the X and Y axes represent the fluorescence intensity, and the numbers in the flow plot represent the frequency of CD19+ B cells among all lymphocytes in the peripheral blood.
See this image and copyright information in PMC

References

    1. Diaz-Manera J, Martinez-Hernandez E, Querol L, Klooster R, Rojas-Garcia R, Suarez-Calvet X, Munoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juarez C, Verschuuren JJ, Illa I. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193. - PubMed
    1. Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16–23. - PubMed
    1. Burns TM, Conaway M, Sanders DB, Composite MG, Group M-QS. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434–1440. - PMC - PubMed
    1. Burns TM, Conaway MR, Cutter GR, Sanders DB. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve. 2008;38(2):957–963. - PubMed
    1. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Annals of the New York Academy of Sciences. 2003;998:440–444. - PubMed

MeSH terms

LinkOut - more resources